Treating COVID-19 long-haulers with Amgen's sleeper heart drug Corlanor

When Amgen won FDA approval for Corlanor (ivabradine) to treat chronic heart failure in 2015, it didn’t generate much enthusiasm in the cardiology community and was quickly overtaken by Novartis’ Entresto, which was seen as having a better risk-benefit profile.

Now, researchers at the University of California, San Diego (UCSD) say they may have found a new market for Corlanor: to treat COVID-19 “long haulers.”